Interim results from a Phase 1 clinical trial of patients with metastatic castration-resistant prostate cancer refractory to prior novel hormonal therapy and 1–2 taxane regimens has found significant anti-tumor activity, with notable declines in prostate-specific antigen levels and partial responses in some patients [42]. This evidence concerns the gene KLK3 and prostate cancer.